RECARBRIO - (EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL ; Powder)

Generic Name	CILASTATIN SODIUM; IMIPENEM; RELEBACTAM	**Innovator**	Merck
Dosage	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL ; Powder	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: ? Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) ? Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ? Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.